Biomarin Pharmaceutical Inc. BMRN

NAS: BMRN | ISIN: US09061G1013   17/04/2026
54,64 USD (+1,00%)
(+1,00%)   17/04/2026
Grafiek Biomarin Pharmaceutical Inc. Grafiek Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc. in het nieuws

12 maart 2026 · BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

28 februari 2026 · U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) · Persbericht

24 februari 2026 · BioMarin to Participate in Four Upcoming Investor Conferences in March · Persbericht

23 februari 2026 · BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results · Persbericht

17 februari 2026 · BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET · Persbericht

12 februari 2026 · BioMarin Announces Closing of Private Offering of Senior Notes · Persbericht

29 januari 2026 · BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility · Persbericht

26 januari 2026 · BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility · Persbericht

12 januari 2026 · BioMarin Appoints Arpit Davé Chief Digital and Information Officer · Persbericht

9 januari 2026 · Veeva et BioMarin forment un partenariat stratégique à long terme · Persbericht

Profiel Biomarin Pharmaceutical Inc.

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.bmrn.com

Hoofdzetel: Novato, California vlag Verenigde Staten

Mijn selecties